A committee of experts voted on a preference for the Moderna or Pfizer immunizations, citing the risk of blood clots linked to Johnson & Johnson’s product.A committee of experts voted on a preference for the Moderna or Pfizer immunizations, citing the risk of blood clots linked to Johnson & Johnson’s product.Vaccination and Immunization, Blood Clots, Coronavirus (2019-nCoV), Deaths (Fatalities), Advisory Committee on Immunization Practices, AstraZeneca PLC, Centers for Disease Control and Prevention, Food and Drug Administration, Johnson & JohnsonRead More
